p 1 1. 2. 3. 4. p 2 p 2 p 2 p 4 1. 2. 3. p 5 p 6 p 6 p 6 p 7 p 8 1. 2. 3. p 8 p 9 p10 p12 p13 p14 p15 p16 p17 p18 p19 p20 p21 p22 p23 p24 p25 p26 p27 p28
-1-
1. 1 1 2. 1 1 300-2-
1 life events 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 1 38 39 40 41 42 43 1 1 250 300 2-3-
-4-3. 1980 1
-5-4. 2 5 2 5 Klaus, K&Kennell, J 1975 V I III II IV
-6-1. 2. 2
3. 1990 19,821 1997 23,494 1998 31,755 2003 34,427 2007 33,093 2011 30,651 2011 4,612 3 1 1958 2 1986 3 1 20 50 60 100% -7-
-8-1. A A 1959 1961!!
-9- Sex DV 2. 3 3
3. 2 4 4 3 1 50% 2 258 2002 303 2005 81 214 2004 65 6.3% 80 20 25% 320 1998 1985 1 240 240 3 10% 10 1 14 15% 7 8 1 0.8%120 1 120 1-10-
-11-4 1995 1% 33% 1% 20% 14% 2% 1% 3%
10% 50 20-30 10 1 4 2 3-6 1-2 4 4 SSRI -12-
-13-30 0.5 1% 100 200 1
-14-20 40 10 15% 1. SAD 2. 3. 1-2
10 20 1 2% ERP -15-
-16-1. 1 48 2. PTSD 1 2 3. PTSD PTSD
1. 2. 3. 2-17-
4-5 1 1. 1 1 1 2. 4 2 1 3. 4 1 2 3 4 5 6 7 8 20-30 -18-
20-30 0.8% 55 1554 120 1 55 120 5 5 3 1 1 70 80% 5!! -19-
2000155 65 7.18% 2020290 65 8.91% 65-69 1.5 % 80-84 14.6 % 70-74 3.6 % 85 27.3 % 75-79 7.1 % 80 4 1!! 1. 2. 5 65 3. 1 2-20-
295 40 14%7 1 1 1 1 500cc 1 AA enabler -21-
220 110!! 1999 3 100 1 120 3 4 5 MDMA NA DARC enabler -22-
100 1 120 550 1-23-
-24-600 1 3 5 100 1 3 3 7 8 3 SST
AD HD 4% 3 11% 4 9 7 SST 10 / -25-
18 6 16% AD HD 3 1 AD HD AD HD 10-26-
-27-100-200 1 1. 2. 3. 5 30 7-8 3-5
GeneralHealth Questionare-12 Goldbrg, 1972 1 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 4 CAGE Questionare Ewing, 1984 C ut down A nnoyed G uilty E 2 ye-opener 2 CAGE -28-
Zung Zung, 1965 1. 2. 3. 1 2 3 4 4 3 2 1 1 2 3 4 4. 4 3 2 1 5. 1 2 3 4 6. 4 3 2 1 7. 1 2 3 4 8. 4 3 2 1 9. 1 2 3 4 10. 4 3 2 1 11. 1 2 3 4 12. 4 3 2 1 13. 1 2 3 4 14. 4 3 2 1 15. 16. 17. 18. 19. 20. 1 2 3 4 4 3 2 1 1 2 3 4 4 3 2 1 1 2 3 4 4 3 2 1 1.25 39 50-29-
-30-
129 2211 143 235 1410 2411 196 253 206 2112 852-8114 10-22 095-846-5115095-846-8920 E-mails04760@pref.nagasaki.lg.jp - 31 -